Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma, Kaposi | 12 | 2023 | 120 | 2.760 |
Why?
|
| HIV Infections | 15 | 2023 | 1858 | 1.470 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2020 | 266 | 1.000 |
Why?
|
| Neoplasms | 7 | 2022 | 2752 | 0.820 |
Why?
|
| Hematology | 3 | 2018 | 36 | 0.800 |
Why?
|
| Anemia, Neonatal | 1 | 2020 | 8 | 0.710 |
Why?
|
| Anemia, Hemolytic | 1 | 2020 | 31 | 0.700 |
Why?
|
| Malawi | 11 | 2023 | 389 | 0.700 |
Why?
|
| Phototherapy | 1 | 2020 | 35 | 0.690 |
Why?
|
| Erythrocyte Transfusion | 1 | 2020 | 122 | 0.640 |
Why?
|
| Hemoglobins | 1 | 2020 | 301 | 0.630 |
Why?
|
| Antineoplastic Agents | 4 | 2020 | 1680 | 0.630 |
Why?
|
| Developing Countries | 3 | 2017 | 270 | 0.600 |
Why?
|
| Medical Oncology | 2 | 2018 | 214 | 0.580 |
Why?
|
| Botswana | 6 | 2020 | 76 | 0.500 |
Why?
|
| Herpesvirus 8, Human | 4 | 2023 | 49 | 0.460 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 1250 | 0.450 |
Why?
|
| Drugs, Essential | 1 | 2013 | 7 | 0.430 |
Why?
|
| Pediatrics | 3 | 2018 | 1139 | 0.420 |
Why?
|
| Anemia | 3 | 2023 | 339 | 0.380 |
Why?
|
| Fibrinolysis | 1 | 2010 | 38 | 0.360 |
Why?
|
| Child | 22 | 2023 | 24108 | 0.360 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2010 | 45 | 0.360 |
Why?
|
| Noonan Syndrome | 1 | 2010 | 29 | 0.360 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2010 | 112 | 0.330 |
Why?
|
| Health Services Accessibility | 2 | 2017 | 586 | 0.320 |
Why?
|
| Child, Preschool | 11 | 2022 | 13837 | 0.290 |
Why?
|
| Vincristine | 2 | 2020 | 208 | 0.290 |
Why?
|
| Hemorrhage | 1 | 2010 | 457 | 0.280 |
Why?
|
| Adolescent | 11 | 2023 | 18971 | 0.230 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 858 | 0.220 |
Why?
|
| HIV-1 | 2 | 2018 | 464 | 0.220 |
Why?
|
| Humans | 29 | 2023 | 122412 | 0.220 |
Why?
|
| Female | 16 | 2023 | 64939 | 0.210 |
Why?
|
| Kasabach-Merritt Syndrome | 1 | 2023 | 16 | 0.210 |
Why?
|
| Male | 16 | 2023 | 59581 | 0.200 |
Why?
|
| Infant | 9 | 2023 | 12347 | 0.200 |
Why?
|
| Wilms Tumor | 1 | 2023 | 116 | 0.190 |
Why?
|
| Retrospective Studies | 9 | 2023 | 15879 | 0.190 |
Why?
|
| Interleukin-6 | 2 | 2019 | 394 | 0.170 |
Why?
|
| Institutional Practice | 1 | 2019 | 6 | 0.170 |
Why?
|
| Bleomycin | 2 | 2020 | 150 | 0.170 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2020 | 62 | 0.170 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2020 | 139 | 0.170 |
Why?
|
| Malnutrition | 1 | 2022 | 196 | 0.170 |
Why?
|
| Infant, Newborn | 4 | 2020 | 8113 | 0.160 |
Why?
|
| Doxorubicin | 1 | 2020 | 307 | 0.160 |
Why?
|
| Retinoblastoma | 1 | 2019 | 108 | 0.160 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 431 | 0.160 |
Why?
|
| Delayed Diagnosis | 1 | 2020 | 121 | 0.150 |
Why?
|
| Anti-HIV Agents | 2 | 2020 | 304 | 0.150 |
Why?
|
| Neoplasm Staging | 2 | 2023 | 1227 | 0.150 |
Why?
|
| Paclitaxel | 2 | 2020 | 122 | 0.150 |
Why?
|
| Hematologic Diseases | 1 | 2018 | 74 | 0.150 |
Why?
|
| Herpesviridae Infections | 1 | 2018 | 144 | 0.140 |
Why?
|
| Viral Load | 1 | 2018 | 384 | 0.140 |
Why?
|
| Vitamin B 12 | 1 | 2016 | 55 | 0.130 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2016 | 39 | 0.130 |
Why?
|
| Hospital Mortality | 1 | 2020 | 996 | 0.130 |
Why?
|
| Risk | 1 | 2017 | 739 | 0.130 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 271 | 0.130 |
Why?
|
| Remission Induction | 1 | 2016 | 301 | 0.130 |
Why?
|
| Critical Care | 1 | 2020 | 647 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2020 | 1160 | 0.120 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 162 | 0.120 |
Why?
|
| Anti-Retroviral Agents | 1 | 2015 | 135 | 0.110 |
Why?
|
| Cytokines | 1 | 2019 | 1288 | 0.110 |
Why?
|
| Secondary Prevention | 1 | 2015 | 208 | 0.110 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2014 | 102 | 0.110 |
Why?
|
| Physicians | 1 | 2019 | 582 | 0.110 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 19 | 0.110 |
Why?
|
| Mouth Neoplasms | 1 | 2013 | 78 | 0.100 |
Why?
|
| Thrombocytopenia | 1 | 2013 | 230 | 0.090 |
Why?
|
| Plasminogen | 1 | 2010 | 7 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2013 | 378 | 0.090 |
Why?
|
| Prothrombin Time | 1 | 2010 | 36 | 0.090 |
Why?
|
| Antithrombin III | 1 | 2010 | 25 | 0.090 |
Why?
|
| Partial Thromboplastin Time | 1 | 2010 | 46 | 0.090 |
Why?
|
| Hemostasis | 1 | 2010 | 67 | 0.090 |
Why?
|
| Prognosis | 2 | 2017 | 4492 | 0.090 |
Why?
|
| Peptide Hydrolases | 1 | 2010 | 141 | 0.080 |
Why?
|
| Adult | 4 | 2023 | 28743 | 0.070 |
Why?
|
| Epilepsy | 1 | 2015 | 859 | 0.070 |
Why?
|
| Africa South of the Sahara | 2 | 2018 | 113 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2006 | 79 | 0.070 |
Why?
|
| Time Factors | 1 | 2016 | 6176 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 801 | 0.060 |
Why?
|
| Imidazoles | 1 | 2006 | 200 | 0.060 |
Why?
|
| Piperazines | 1 | 2006 | 227 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2020 | 5970 | 0.060 |
Why?
|
| Tanzania | 1 | 2023 | 66 | 0.050 |
Why?
|
| Young Adult | 2 | 2020 | 8805 | 0.050 |
Why?
|
| Nephrectomy | 1 | 2023 | 172 | 0.050 |
Why?
|
| Neuroblastoma | 1 | 2006 | 511 | 0.050 |
Why?
|
| Aged | 1 | 2018 | 18779 | 0.050 |
Why?
|
| Virus Replication | 1 | 2023 | 603 | 0.040 |
Why?
|
| Nutritional Status | 1 | 2022 | 296 | 0.040 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 30 | 0.040 |
Why?
|
| Apoptosis | 1 | 2006 | 1795 | 0.040 |
Why?
|
| Patient Admission | 1 | 2020 | 184 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2023 | 1233 | 0.040 |
Why?
|
| Capacity Building | 1 | 2018 | 19 | 0.040 |
Why?
|
| Middle Aged | 1 | 2018 | 25588 | 0.040 |
Why?
|
| Endemic Diseases | 1 | 2018 | 58 | 0.040 |
Why?
|
| Virus Activation | 1 | 2018 | 86 | 0.040 |
Why?
|
| Patient Care | 1 | 2018 | 99 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2020 | 475 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2020 | 521 | 0.030 |
Why?
|
| Asia | 1 | 2017 | 105 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 1146 | 0.030 |
Why?
|
| Europe | 1 | 2017 | 370 | 0.030 |
Why?
|
| HIV | 1 | 2017 | 179 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 268 | 0.030 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2020 | 441 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 3305 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 1364 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 2369 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 506 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2014 | 156 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 2016 | 663 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 2001 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2020 | 12035 | 0.020 |
Why?
|
| Recurrence | 1 | 2014 | 1412 | 0.020 |
Why?
|
| United States | 1 | 2023 | 10475 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 3231 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 7101 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2006 | 57 | 0.020 |
Why?
|
| Risk Factors | 1 | 2020 | 9868 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2006 | 233 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2006 | 714 | 0.010 |
Why?
|
| Mice | 1 | 2006 | 17638 | 0.010 |
Why?
|
| Animals | 1 | 2006 | 33898 | 0.000 |
Why?
|